Facility Safety Plan B360 Complex Biohazardous Operations CMLS-412r0 by Cooper, G
UCRL-TR-227218
Facility Safety Plan B360
Complex Biohazardous
Operations CMLS-412r0
G.A. Cooper
January 11, 2007
Disclaimer 
 
 This document was prepared as an account of work sponsored by an agency of the United States 
Government. Neither the United States Government nor the University of California nor any of their 
employees, makes any warranty, express or implied, or assumes any legal liability or responsibility for 
the accuracy, completeness, or usefulness of any information, apparatus, product, or process 
disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any 
specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise, 
does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United 
States Government or the University of California. The views and opinions of authors expressed herein 
do not necessarily state or reflect those of the United States Government or the University of California, 
and shall not be used for advertising or product endorsement purposes. 
 
 
 
 
 This work was performed under the auspices of the U.S. Department of Energy by University of 
California, Lawrence Livermore National Laboratory under Contract W-7405-Eng-48. 
 
FSP-360.1 
ISSUED 12/2006 
Triennial Review 
 
CMLS-412r0: Building 360 Complex Biohazardous Operations 
 
 
 
 
 
 
 
 
 
 
 
 
Building 360 Complex 
 
 
Biohazardous Operations 
 
 
 
 
 
 
 
 
 
 
December 2006 
 
 
 
 
 
 
Lawrence Livermore National Laboratory 
Lawrence Livermore National Laboratory Effective: 12/06 
Facility Safety Plan 360.1 Expires: 12/31/09 
Building 360 Complex, Biohazardous Operations 
 
 
 
 
Disclaimer 
 
This document was prepared as an account of work sponsored by an agency of the United States 
Government. Neither the United States Government nor the University of California nor any of 
their employees, makes any warranty, expressed or implied, or assumes any legal liability or 
responsibility for the accuracy, completeness, or usefulness of any information, apparatus, 
product, or process disclosed, or represents that its use would not infringe privately owned rights. 
Reference herein to any specific commercial products, process, or service by trade name, 
trademark, manufacturer, or otherwise, does not necessarily constitute or imply its endorsement, 
recommendation, or favoring by the United States Government or the University of California. 
The views and opinions of authors expressed herein do not necessarily state or reflect those of 
the United States Government or the University of California, and shall not be used for 
advertising or product endorsement purposes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Work performed under the auspices of the U.S. Department of Energy by Lawrence Livermore 
National Laboratory under contract W-7405-ENG-48. 

Lawrence Livermore National Laboratory Issued: 12/06 
Facility Safety Plan 360.1 Expires: 12/31/09 
Building 360 Complex, Biohazardous Operations  
 
 
CONTENTS 
 
1.0 Introduction................................................................................................ 1 
1.1 Purpose ...........................................................................................................................1 
1.2 Applicability ...................................................................................................................1 
1.3 Changes...........................................................................................................................1 
1.4 Review ............................................................................................................................1 
2.0 Scope ........................................................................................................... 2 
2.1 Authorized Operations.....................................................................................................2 
3.0 Hazards Analysis ........................................................................................ 3 
3.1 General............................................................................................................................3 
3.2 Biohazards (Etiological Agents) .....................................................................................3 
3.3 Human Blood and Bodily Fluids .....................................................................................6 
3.4 Recombinant DNA Experiments......................................................................................7 
3.5 Cell (Tissue) Culture Lines .............................................................................................7 
3.6 Human Subjects ..............................................................................................................8 
3.7 Animals...........................................................................................................................8 
3.8 Hazardous Materials........................................................................................................8 
4.0 Responsibilities and Authorities ................................................................ 9 
5.0 Health & Safety Controls......................................................................... 10 
5.1 Administrative Controls ................................................................................................10 
5.2 Engineering Controls.....................................................................................................18 
5.3 Personal Protective Equipment ......................................................................................19 
6.0 Emergency Controls ................................................................................ 21 
6.1 Handling Spills..............................................................................................................21 
7.0 Environmental Concerns and Controls .................................................. 22 
8.0 Emergency Response................................................................................ 23 
9.0 Maintenance, Inspection, and Quality Assurance of Safety Systems and 
Equipment.................................................................................................. 24 
10.0 Training ................................................................................................................... 25 
11.0 References ............................................................................................................... 26 
Appendices.......................................................................................................... 27 
Appendix A: Vacuum Line Filter............................................................................................27 
Appendix B: Universal Precautions ........................................................................................28 
Appendix C: Disinfectants ......................................................................................................29 
Appendix D: Emergency Response .........................................................................................32 
Appendix E Biological Safety Cabinets: Procedures for Effective Use .................................34 
Appendix F: Biological Safety Cabinets: Necropsy Rules for Infected Animals .....................36 
 
Lawrence Livermore National Laboratory Issued: 12/06 
Facility Safety Plan 360.1 Expires: 12/31/09 
Building 360 Complex, Biohazardous Operations Page 1 of 36 
 
 
1.0 Introduction 
1.1 Purpose 
This Addendum to the Facility Safety Plan (FSP) 360 Complex describes the safety 
requirements for the safe conduct of all biohazardous research operations in all buildings 
within the 360 complex program areas. These requirements include all the responsibilities 
and authorities of building personnel, operational hazards, and environmental concerns 
and their controls. In addition, this Addendum prescribes facility-specific training 
requirements and emergency controls, as well as maintenance and quality assurance 
requirements for ES&H-related building systems. 
The controls established in this FSP addendum conform to FSP 360 and the ES&H 
Manual.  
1.2 Applicability 
This Addendum covers biohazardous operations in facilities assigned to 360 complex 
programs. 
Safety requirements in this FSP Addendum and the ES&H Manual shall apply to all 
participants in 360 complex program operations and individual users of 360 complex 
facilities. This includes staff members, contract workers, support and service staff, 
participating guests, short-term & long-term visitors, and summer students. Floor plans 
for all buildings occupied or controlled by the CMLS Directorate are available from the 
Facility Point of Contact (FPOC). 
1.3 Changes 
Any changes in operations that increase the hazard level, introduce additional hazards, or 
decrease safety shall not be made until a revision of or supplement to this FSP addendum 
has been reviewed and approved consistent with the review and approval process for the 
original FSP. Proposed changes in building safety and environmental control systems 
require a design review and must be approved by the Facility Manager. 
1.4 Review 
This FSP addendum will be formally reviewed and reissued at a minimum of every three 
years to ensure that its contents are appropriate and adequate for current operations. If 
changes are necessary before the triennial review date, the FSP will be amended and the 
changes approved by the Associate Director for CMLS Programs. 
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2.0 Scope 
2.1 Authorized Operations 
This addendum to FSP 360 approves biohazardous operations that are limited to 
Biosafety Level (BSL) 1 or 2 activities and are limited to small-scale, non-production 
research-laboratory scale amounts. For complete definitions of biosafety levels, refer to 
Document 13.6, “Safe Handling and Use of Biological Research Materials,” of the ES&H 
Manual. 
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3.0 Hazards Analysis 
3.1 General 
The hazards associated with working with biohazardous agents will vary from personal 
exposure to accidental environmental releases. Personal exposure may result from the 
handling of toxic chemicals, infectious agents, animals, toxic gases, or extremely hot or 
cold objects. The degree of personal exposure will depend on infectious-contaminated 
sources, immune status of the host, and efficiency of the transmission of infection.  
Accidental releases into the environment may cause an imbalance of the normal 
established micro-flora for a specific area. This may have an impact on specific food 
industries, sewage treatment facilities, and may pose a threat to the public health of the 
general public and to those individuals who may be immunologically compromised. 
Because of the serious ramifications to employee exposure and accidental releases into 
the environment, control measures required to prevent such events from occurring are 
now mandated by law. 
3.2 Biohazards (Etiological Agents) 
Biohazards are often referred to as etiological agents. Biohazards include both 
biohazardous materials and biological agents. Biohazards mean any biological material or 
their components that present a real potential risk of illness or injury to humans, plants, 
and animals. A summary of materials and controls are listed in Table 1 in Section 3.2.2.2.  
3.2.1 Biohazardous Materials 
Biohazardous materials are not capable of self-replication and are the 
components of biological agents that present a real or potential risk of causing 
illness or injury to humans, plants, and animals.  
3.2.1.1 Biological Toxins or Biotoxins 
Biological toxins or biotoxins are non-living biohazardous (toxic) 
proteins that are naturally produced by many different types of living 
organisms and are thousands of times more toxic by weight than 
chemical agents. Toxins (themselves) are not infectious or contagious 
to other host after exposure. However, the presence of toxin producing 
organisms may be infectious or contagious to a host after exposure. 
3.2.1.2 Endotoxins 
Endotoxins are associated with the outer membrane of certain gram- 
negative bacteria and are released only when the cells are disrupted. 
Endotoxins are not secreted. They are composed of complex 
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polysaccharides molecules responsible for eliciting an antigenic 
response resulting in fever, and altered resistance to bacterial 
infections. Exposure to large quantities may result in toxic 
hemorrhagic shock and severe diarrhea.  
3.2.1.3 Clinical and Diagnostic Specimens 
A diagnostic specimen is any human or animal material including but 
not limited to, excreta, secreta, blood, components, tissue, and tissue 
fluids, being handled for the purposes of diagnosis. Clinical and 
diagnostic specimens from human and animal sources may be 
hazardous. Typically, the infectious nature of clinical material is 
unknown and may contain potential human pathogens requiring 
specific handling procedures. For further description, see Document 
13.2, “Exposure Control Plan - Working Safely with Blood and Blood 
borne Pathogens,” of the ES&H Manual. 
3.2.2 Biohazardous Agents 
Biohazardous agents are biological in nature, usually capable of self-replication 
and have the capacity to produce deleterious effects on other biological 
organisms, particularly humans. They include, but are not limited to, various 
viruses, prions, chlamydia, bacteria, fungi, yeast, algae, plants, animals, and any 
products that may contain any of these agents. 
Factors to be considered in determining the level of containment include agent 
factors such as virulence, pathogenicity, infectious dose, environmental 
stability, route of spread, communicability, operations, quantity, availability of 
vaccine or treatment, and gene product effects such as toxicity, physiological 
activity, and allergenicity.  
3.2.2.1 CDC and NIH's Classification of Etiologic Agents 
The CDC and NIH have classified etiological agents into 4 Risk 
Groups. An organism of higher classification would indicate a higher 
level of hazard or higher risk group. 
Risk Group (RG) 1: Agents not associated with disease in healthy 
human adult. 
Risk Group (RG) 2: Agents that are associated with human disease 
that is rarely serious for which preventive or 
therapeutic interventions are often available.  
Risk Group (RG) 3: Agents that are associated with serious or lethal 
human disease for which preventive or 
Lawrence Livermore National Laboratory Issued: 12/06 
Facility Safety Plan 360.1 Expires: 12/31/09 
Building 360 Complex, Biohazardous Operations Page 5 of 36 
 
 
therapeutic intervention may be available (high 
individual risk but low community risk). 
Risk Group (RG) 4: Agents that are likely to cause serious or lethal 
human disease for which preventive or therapeutic 
intervention are not available (high individual risk 
and high community risk). Prohibited at LLNL. 
TABLE 1: CLASSIFICATION OF CURRENT RESEARCH IN 360 complex 
Examples Biosafety Level 1 Biosafety Level 2 
Laboratories Basic Teaching Human Blood, Blood Products & 
Body Fluids 
  Hospital Diagnostic 
  Teaching and Public Health 
Laboratory Work 
practices 
Good Microbiological 
Practices 
Good Microbiological Practices, 
Protective Clothing, and Biosafety 
Signs 
Safety Equipment None, Open Bench 
Work Permitted 
Open Bench Work Plus Biological 
Safety Cabinets for Potential Aerosols 
Etiological Agents, 
bacterial Viruses and 
Plasmids - Some with 
Mammalian DNA Inserts 
Risk Group 1 Agents Risk Group 2 Agents 
 Lamda  
 M13  
 P1  
 pBR322  
Mammalian Cell Lines CHO, V79 Epstein-Barr Transformed 
Lymphoblastoid Cells 
 CHO-Human Hybrids  
 Mouse Myeloma Viable Human Tumor, or Human 
Tumor Cells  
 Mouse Tumor Cells  
 Mouse Lymphoma  
 Mouse Tissues  
  Viable Samples of Human and 
Primate, Bone, Marrow, Serum, 
Semen, Blood, Urine, and Other 
Potentially Infectious Cells/ Secretions 
  Untransformed Normal Human Cell 
Lines (Except for Lymphoblastoid 
Cells) 
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TABLE 1: CLASSIFICATION OF CURRENT RESEARCH IN 360 complex 
Examples Biosafety Level 1 Biosafety Level 2 
 Fixed Human/Primate 
Tissues 
Unfixed Human/Primate Tissues 
Oncogenic Viruses  Low Risk and Moderate Risk 
Oncogenic Virus 
3.2.2.2 NCI Classification of Oncogenic Viruses 
 The National Cancer Institute (NCI) has defined oncogenic viruses as 
a special class of etiologic agents that have been categorized into 3 
classifications of risk: Low Risk, Moderate Risk, and High Risk 
(Section 11, Ref. 11.3). 
3.3 Human Blood and Bodily Fluids 
 
Human blood and human body fluids have been determined by the Occupational Safety 
and Health Administration (OSHA) to be potentially contaminated with blood borne 
pathogens (4). As listed in Table 2, blood borne pathogens include, but are not limited to, 
the Hepatitis B Virus, Hepatitis C Virus, and the Human Immuno-deficiency Virus. See 
Document 13.2, “Exposure Control Plan: Working Safely with Blood and Bloodborne 
Pathogens,” of the ES&H Manual for more information regarding blood borne 
pathogens. 
 
TABLE 2: LIST OF BLOODBORNE PATHOGENS (1,2,5) 
Disease/ Agent(s) Common Names  Risk  Incubation  Sources (*) 
Serum Hepatitis/  
Hepatitis B Virus 
Hepatitis B (42 nm) 
Hepadnavirus dsDNA 
 6-10% 
1-
2%Fatal 
11 weeks Blood, cerebral 
spinal fluid (CSF), 
Semen, Saliva 
Transfusion Hepatitis/ 
 Hepatitis C Virus  
 Hepatitis C, Non A-Non B 
(40-60 nm) Flaviviridae (ss 
RNA) 
0.5-1% 
Fatal 
7 weeks Blood, Serum 
AIDS: 
Retroviridae(100 nm) 
(Oncornavirus - RNA) 
HIV - 1, LAV (formally HTLV 
3) 
< 0.5% 
100% 
Fatal 
Adults: 8 yrs 
Infanst: 2 yrs 
Blood, Serum, CSF 
Saliva, Tears, Urine, 
Breast Milk, 
Amniotic Fluid.,  
 HIV-2 (West Africa) HTLV IV  <8.9% 
100% 
Fatal 
Unknown Blood, Serum, CSF 
Saliva, Tears, Urine, 
Breast Milk, 
Amniotic Fluid  
Leukemia/  
Lymphomas Human T 
- Lymphotropic Virus  
Retroviridae(Oncornavirus 100 
nm) HTLV I  
 
18-49% 
 
Unknown 
 
Blood 
 HTLV II 52% Unknown Blood 
 HTLV V Unknown Unknown Blood 
* - Human sources are noted unless otherwise stated. 
      These human materials are not considered biohazardous unless either diagnosed with disease or there  
      is strong reason to suspect disease is present 
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3.4 Recombinant DNA Experiments 
Recombinant DNA experiments include any experiments involving the construction and 
handling of recombinant DNA molecules, organisms, and viruses containing recombinant 
DNA molecules and work involving gene therapy. Recombinant DNA molecules is 
defined as either:  
(i) molecules that are constructed outside living cells by joining natural or synthetic DNA 
segments to DNA molecules that can replicate in a living cell, or 
(ii) molecules that result from the replication of those described in (i) above.  
The molecules that are expressed from synthetic or recombinant DNA that are likely to 
yield a potential harmful polynucleotide or polypeptide (e.g., a toxin or a 
pharmacologically active agent) are considered as equivalent to their natural DNA 
counterparts. They are considered to be in the same risk group as those of the original host 
organism in which the DNA was found. Recombinant DNA experiments may involve 
microbial, animal, or plant host. In accordance with NIH guidelines (Section 11, Ref. 
11.8), all work involving recombinant DNA must be submitted to the Institutional 
Biosafety Committee (IBC). 
3.5 Cell (Tissue) Culture Lines 
Cell culture lines are known to harbor latent viruses adventitiously or from deliberate 
experimental infections and pose a potentially undetected hazard. Established cell lines of 
sub-primate or normal primate origin that do not harbor a primate virus (and are not 
contaminated with bacteria or fungi of greater than BSL-1) may be handled in a BSL-1 
containment facility. Primary and permanent human or animal cell lines may be regarded 
as carrying Class 1 oncogenic viruses unless they are known to be infected with a more 
hazardous agent(s).  
Permanent human lymphocyte cell cultures or primate cell lines derived from lymphoid 
or tumor tissue should be handled with the assumption that they harbor the Risk Group 2 
agent, Epstein barr virus, (EBV). Additionally, all cell lines that have been converted, 
exposed, or transformed by a primate oncogenic viruses; and all new cell lines must be 
handled in a BSL2 containment facility. Under no circumstances shall anyone work with 
cells derived from themselves or from first-degree relatives, since the host immune 
system may not provide adequate protection. 
3.6  Human Subjects 
Work with human subjects requires approval from the Institutional Review Board (IRB). 
The IRB ensures that the rights of human subjects are protected and to assure their 
informed voluntary consent to participate in human subjects research is also protected. 
3.7 Animals 
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Working with animals poses unique hazards to researchers, the animals themselves, and 
to Animal Care Facility personnel handling the animals. Special care should be taken to 
limit exposure to zoonotic agents that exist as animal flora. Experimental work with any 
animal requires the approval from the Institutional Animal Care and Use Committee 
(IACUC) to ensure the humane care of animals and experimentation (Section 11, Ref. 
11.6). 
3.8 Hazardous Materials 
Working with biohazardous materials often requires working with radioactive and 
hazardous materials. The hazards dealing with radioactive material and/or hazardous 
materials are discussed in Section 5.0, “General Building Safety Limits and Controls,” of 
FSP 360. 
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4.0 Responsibilities and Authorities  
Overall responsibility within the Biosciences Program is discussed in Section 4.0, 
“Responsibilities and Authorities,” of FSP 360. 
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5.0 Health and Safety Controls 
5.1 Administrative Controls 
5.1.1 Protocol Review Process 
All research activities involving the use of human subjects, animal subjects, and 
biohazardous materials or DNA technology will require institutional review 
with the LLNL Biosafety Operations Committee (LBOC), and approved by the 
Institutional Review Board (IRB), Animal Care and Use Committee (IACUC), 
and the Institutional Biosafety Committee (IBC), respectively. Contact the area 
Industrial Hygienist supporting for more information on working with these 
committees. 
• The LLNL Biosafety Operations Committee (LBOC) provides 
experimenters with an initial single point of contact, determines the level of 
required review, identifies the associated hazards, recommends the level of 
training required, recommends the need for medical surveillance, proposes 
changes to the ES&H Manual, and addresses biosafety issues requested by 
Council of Biosciences and Biotechnology 
• Institutional Review Board (IRB): Federal regulations and Laboratory 
policy require that approval by the IRB be obtained before any research 
project involving use of human subjects or human tissue be initiated in order 
to protect the rights and welfare of individuals who volunteer to become 
subjects in research projects. 
• Institutional Animal Care and Use Committee (IACUC): Approval by the 
IACUC shall be obtained prior to initiating any research involving 
vertebrate animals. The IACUC must determine if the proposed work meets 
acceptable standards for the care and use of animals in research. 
• Institutional Biosafety Committee (IBC): The IBC shall review all research 
protocol involved in the use of recombinant DNA technology, artificial gene 
transfer, biological agents (bacteria, viruses, protozoa, fungi, etc.), toxins 
(natural and synthetic), and biological materials from human and animal 
sources (e.g., tissues, body fluids, cell cultures, etc.). Federal regulations 
under 29 CFR 1910.1030 require that any work with human blood, other 
human materials, or human blood borne pathogens and under 42 CFR Part 
72 for any work with infectious materials be reviewed to determine 
exposure potential for workers. The IBC approves and/or registers all 
biological research at LLNL. In addition, the IBC is responsible for 
determining whether a protocol complies with applicable rules and 
regulations and that it meets appropriate biosafety containment standards as 
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set forth by the National Institutes of Health (NIH) Guidelines on 
recombinant DNA. 
CMLS review. The administrative control first used to mitigate hazards is the 
initial Integration Worksheet (IWS) that is prepared by the RI and reviewed by 
Program Management with assistance from the ES&H Team. Operations 
covered under this FSP will require an IWS to determine if a supplemental SP 
will be required. 
5.1.2 Work Practice Controls 
Work with biohazardous agents and/ or materials on site and will be limited to 
Biosafety Level (BSL) 1 or 2 Containment Levels. Appropriate BSL work 
practices and containment guidelines will be followed and are summarized in 
Section 3.2.2.2, Table 1 (Section 11, Refs. 11.8 & 11.9). 
Universal precaution is an approach to infection control in which all human 
blood and certain human body fluids are treated as contaminated with blood 
borne pathogens. Universal Precaution work practices are listed in Appendix B 
of this document.  
Frequent hand washing is encouraged. Hands should be washed with soap and 
water after removing gloves, after handling potentially infectious materials, and 
before leaving the laboratory. 
Animals: All research animals are routinely handled in accordance with existing 
regulation guidelines (Section 11, Ref. 11.6), and LLNL Animal Care Facility 
Standard Operating Procedures. As a result, all animals are quarantined for a 
period of 7-14 days before being used as part of the research protocol. 
Appropriate animal biosafety levels are assigned in accordance to the hazard. 
Decontamination: All surfaces must be decontaminated before initiating any 
work and at the end of each workday. There are 3 levels of biological 
decontamination of microorganisms (see below). The preferred method for 
activities covered under this FSP is disinfection unless working in a sterile 
environment.  
1. Sanitization: Involves the general reduction of microorganisms by use of 
general cleaning agents. 
2. Disinfection: Involves the destruction of targeted organisms with the use of 
chemicals or physical agents. For example, table tops and surfaces can be 
decontaminated with disinfectants such as amphyl or broccal. 
3. Sterilization: Sterilization is the complete destruction of all microbes and is 
generally used in the total decontamination process. 
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Biohazard Signs must be placed at the entry of each laboratory where Risk 
Group 2 biohazardous materials are handled or stored. The biohazard symbol 
(see Figure 1 below) is used as a warning sign. The sign should indicate the 
biohazard present, the person(s) responsible for the work, and any restrictions 
on access to the room. The biohazard symbol is normally red on a white field. 
The sign is not to be placed at the entry of laboratories where only Risk Group 1 
are handled or stored. 
 
Figure 1 
5.1.3 Medical Waste Management 
Medical waste is a unique category of waste, which is regulated by California’s 
Department of Health Services (DHS) and enforced by Alameda County Health 
Care Services Agency for the LLNL Main Site and enforced by the San Joaquin 
County Public Health Services for Site 300. In addition to the guidance 
described below on management of these wastes, refer to Section 5.8, 
“Environmental Hazards and Controls” of the Building 360 FSP, and the 
ES&H Manual, Document 36.1, “Hazardous, Radioactive, and Biological 
Waste Management Requirements,” Section 3.0, “Administrative Controls.” 
Medical waste consists of biohazardous waste, sharps waste contaminated with 
a biohazardous component, and trauma scene waste. Definitions of each waste 
type are included in the following sections. 
5.1.3.1 Biohazardous Waste (includes any of the following) 
• Animal parts, tissues, fluids, or carcasses that are known to be 
infected with diseases that are highly communicable to humans. 
• Laboratory wastes containing human or animal specimen 
cultures, cultures and stocks of infectious agents, and waste from 
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the production of bacteria, viruses, and spores, discarded human 
or animal vaccines, and culture dishes. 
• Recognizable human blood, in fluid form, and items containing 
enough human blood that the item releases the blood upon 
compression (i.e., soaked bandages or clothing). 
• Human or animal excretion, exudate, or secretions required to be 
isolated by infection control staff. 
• Human surgery specimens or tissues removed at surgery or 
autopsy suspected of being contaminated with infectious agents 
communicable to humans. 
5.1.3.2 Sharps Waste 
Sharps waste is any device having acute, rigid corners, or edges 
capable of cutting or piercing. Sharps wastes contaminated with 
biohazardous components are regulated as medical wastes. Examples 
of regulated sharps wastes include the following: 
• Broken glass items, such as blood vials and pipettes, 
contaminated with biohazardous waste. 
• Discarded hypodermic needles, syringes, blades, and needles 
with attached tubing, and scalpels that have been contaminated 
with biohazardous wastes.  
5.1.4 Medical Waste Accumulation and Storage 
5.1.4.1 Biohazardous Waste 
• Biohazardous wastes must be collected in red biohazard bags 
labeled with the words "biohazardous waste" or with the 
international biohazard symbol and the word "biohazard" and 
placed inside rigid containers with appropriate labeling. Double-
bagging is often a best management practice to prevent leakage 
of the waste into the rigid container.  
• The rigid leak-proof container must be labeled with the words 
"biohazardous waste" or with the international biohazard symbol 
and the word "biohazard" on the lid and on all the sides.  
• Biohazardous waste should be disposed on a daily basis, 
however, for large quantity generators (all programs at the LLNL 
main site), biohazardous waste may be accumulated for up to 7 
calendar days after the first waste article is placed in the 
container if the waste is accumulated above 0°C. (Biohazardous 
waste may be accumulated for up to 90 days below 0°C if freezer 
space is available). 
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• For small quantity generators (Site 300), biohazardous waste 
may be accumulated for up to 30 calendar days after the first 
waste article is placed in the container if the waste is 
accumulated above 0°C. (Accumulate such waste for 90 days if 
accumulated below 0°C).  
• If the waste contains hazardous and/or radioactive components, 
as well as medical waste components, the waste may be subject 
to hazardous, radioactive, or mixed waste regulations, rather than 
the medical waste regulations. Contact the area Environmental 
Analyst for assistance in the characterization of waste and 
decontaminating procedures to be performed prior to Radioactive 
and Hazardous Waste Management’s (RHWM) receipt of non-
medical wastestreams described in the section above. 
5.1.4.2 Sharps Waste 
• Biohazardous sharps wastes must be collected at the site of 
generation and accumulated and stored in red, leakproof puncture 
resistant sharps containers that are labeled as “Sharps Waste” or 
with the international biohazard symbol and the word 
“biohazard.” 
• Non-biohazardous sharps waste must also be collected in rigid 
sharps containers. However, these sharps containers should be of 
any color other than red and should not contain the embossed 
biohazard symbol on the container, but rather the appropriate 
label that represents the characterization of the waste (i.e., 
hazardous waste label, radioactive waste label, mixed waste 
label, or nonhazardous waste label).  
• Sharps wastes contaminated with biohazardous components 
which are accumulated above 0°C (at room temperature) in the 
red sharps containers may accumulate until the container reaches 
the 3/4 fill-line. Sharps wastes which are accumulated above 0°C 
must be treated within 7 calendar days after the waste container 
is 3/4 full. However, if freezer space is available, sharps wastes 
may be transferred to the freezer and stored below 0°C for up to 
90 days after the container becomes 3/4 full following the 
accumulation time at room temperature. The waste must then be 
treated by the end of the 90-day storage period. Note that once 
the container becomes 3/4 full at room temperature, the waste 
must be transferred to the freezer within seven days from that 
day so that the treatment time-limit is not exceeded. If the 
container is stored at room temperature for any time once the 
container becomes 3/4 full prior to transfer to the freezer, the 
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period of time the container is stored at room temperature must 
be included as part of the 90 day storage timeframe in the 
freezer. 
• Home-generated sharps (i.e., syringes used for self-medicating 
purposes) must also be disposed of in rigid sharps containers. 
However, syringes used for self-medicating purposes may not be 
disposed of through LLNL. LLNL currently does not supply 
individuals who generate such syringes with red rigid sharps 
containers. These individuals are responsible for obtaining their 
own personal impervious containers for home-generated sharps 
wastes and disposing the containers appropriately at home. The 
local waste management service at home can provide individuals 
with home-generated sharps disposal guidance. 
5.1.5 Medical Waste Disposal 
Medical waste generated at various locations at the LLNL main site are 
transported to the B-360 Complex every Wednesday before 9:00 a.m. where the 
waste is treated by steam sterilization (autoclaving). Note: waste containing a 
medical waste component and hazardous, radioactive, mixed (radioactive and 
hazardous), or California combined (radioactive and regulated as hazardous 
only by California) is not considered medical waste and is not autoclaved. 
Instead, it is managed through Radioactive and RHWM using a waste disposal 
requisition (WDR) as described in FSP 360. The biohazardous component must 
be eliminated through disinfection prior to disposal through RHWM. Contact 
the area Industrial Hygienist prior to adding disinfectant to ensure the 
disinfectant will not adversely react with any chemical components in the waste. 
Specific type, concentration, and volume of the disinfectant used must be noted 
on the WDR prior to submittal of the WDR to RHWM for approval. 
5.1.5.1 Biohazardous Waste 
• Solid biohazardous waste is autoclaved in special autoclaves 
permitted by Alameda County Health Care Services Agency and 
then placed in the municipal trash. 
• Liquid biohazardous waste may be disposed of into the sanitary 
sewer on a case-by-case basis following proper decontamination 
procedures and prior approval from the area Environmental 
Analyst. 
 
5.1.5.2 Sharps Waste 
Sharps waste containing only biohazardous components are first 
autoclaved in special autoclaves permitted by Alameda County 
Health Care Services Agency to eliminate the biohazardous 
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component and are then sent offsite for incineration through 
RHWM. Generators are required to complete waste disposal 
requisition forms for all sharps wastes generated at LLNL 
5.1.5.3 Liquid Biohazardous Waste 
Liquid biohazardous waste must have the biohazard destroyed by 
adding bleach at a concentration agreed to by the area Industrial 
Hygienist (typically a 10% final concentration of household bleach). 
Once decontaminated, the waste shall be placed in an appropriately 
labeled (nonhazardous or radioactive waste label) waste container. 
Contact the RHWM technician to provide the waste containers and 
for more information regarding disposal of specific items. Note: Use 
of disinfectant to destroy the biohazard in a waste that is also 
hazardous requires special procedures be followed. Contact the area 
environmental analyst in such a case. 
5.1.6 Medical Waste Documentation 
LLNL main site medical waste generators are required to maintain an updated 
waste treatment record to ensure that their waste was successfully sterilized (by 
permitted autoclave) within the regulatory timeframes. Current generators use a 
standard log to maintain such information. 
Operators of autoclaves used onsite to sterilize medical waste are responsible 
for ensuring that the following autoclave recordkeeping requirements are met: 
• Annual autoclave calibration with records, 
• Monthly Bacillus stearothermophilus ampule test with records, 
• Records of heat-sensitive tape results for each waste load that is autoclaved. 
5.1.7 Decontamination 
Reusable rigid secondary containers used to hold biohazardous waste shall be 
thoroughly washed and decontaminated at least monthly and whenever a work 
contamination is noted (e.g., leaky bags), unless the surfaces of the container 
have been completely protected from contamination by disposable liners, bags, 
or other devices removed with the waste. Approved methods of 
decontamination include the following: 
• Exposure to hot water of at least 82 degrees centigrade (180 degrees 
Fahrenheit) for a minimum of 15 seconds, or  
• Exposure to chemical sanitizers (i.e., rinsing with or immersion in) a 
solution containing one of the following for at least 10 minutes: 
• Quaternary ammonium solution (400 ppm active agent) 
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• Iodoform solution (100 ppm available iodine) 
• Phenolic solution (500 ppm active agent) 
• Hypochlorite solution (10% aqueous solution of household bleach that 
contains 5% hypochlorite) 
5.1.8 Environmental Protection Department Contacts 
Please contact the area Environmental Analyst for information regarding 
medical waste management, including waste characterization, storage 
procedures, and preparation for waste treatment or disposal. The area RHWM 
field technician can assist in ensuring receipt of proper biohazardous and sharps 
containers, labels, and waste disposal requisition forms which must accompany 
all sharps wastes and biohazardous wastes with a hazardous or radioactive 
component. 
5.1.9 Transportation 
Transportation of biological material must be performed in a manner that does 
not pose a threat or injury to personnel and property. Transportation of such 
materials involves the use of both proper packaging and shipping. 
Onsite transportation of biological materials is performed using labeled, leak-
proof secondary containers. Hazardous and biohazardous materials, substances, 
and/or wastes, excluding analytical samples, may not be transported in bicycle 
baskets, lab coats, automobiles, or personal vehicles. For more information on 
the transportation of chemical and biological materials, see Document 21.2, 
“Onsite Hazardous Material Packaging and Transportation Safety Manual,” in 
the ES&H Manual. 
Offsite transportation of articles or substance that are likely to pose a significant 
risk to health, safety, property, or the environment shall comply with the 
applicable regulations of the Department of Transportation (DOT), International 
Civil Aviation Organization (ICAO), U.S. Department of Agriculture (USDA), 
and the Centers for Disease and Control (CDC). Offsite shipping of biological 
and chemical materials must be done in accordance with Document 21.1, 
“Acquisition, Receipt, Transportation, and Tracking of Hazardous Materials,” in 
the ES&H Manual. For specific packaging and shipping procedures, contact 
either the LLNL Transportation Office or the Materials Management 
Department. 
5.1.10 Medical Surveillance 
Staff who work with pathogens, human blood, or other human bodily fluids will 
be offered vaccination (i.e., the Hepatitis B Vaccine: 3 injections over 6 months) 
to prevent illness in the event of accidental infection. Additional information 
regarding the vaccine can be obtained from the Health Services Department. 
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5.2 Engineering Controls 
5.2.1 Engineering controls required for work with biohazardous materials include all 
requirements associated with working with hazardous materials. Engineering 
controls, in combination with safe work practices that alter the manner in which 
tasks are performed, are expected to be primary means of eliminating or 
minimizing the risk of occupational exposure. Engineering controls are used to 
isolate or remove hazards from the workplace in order to reduce the potential 
for exposure. Such engineering controls include, but not limited, to mechanical 
aids, dead air boxes, laboratory-type fumehoods, biological safety cabinets 
(BSC), and negative air flow units, which are discussed in detail on the 
following page. 
• Mechanical Aid– Mouth-pipetting of any substance is prohibited and the use 
of mechanical aids to transfer potentially harmful substances (i.e., 
biohazardous) is strictly enforced. Use of aerosol-resistant tips and aerosol-
reducing practices shall be implemented whenever practicable. Personnel 
shall use these devices for all pipetting. 
• Dead Air Boxes–Dead air boxes are commonly used to reduce the potential 
of contamination while diluting or transferring stock concentrations of 
biohazardous materials. Work areas must be decontaminated before and 
after each use to reduce the likelihood of cross-contamination. 
• Fume hoods–Fume hoods are commonly used in the laboratory to draw air 
away from the work area. Fumehoods are available in most laboratories 
within CMLS and must not be used for long-term storage of materials and 
equipment merely as a matter of convenience. Fume hoods are not to be 
used for biohazardous operations. 
• Negative Air-Flow Unit–All animals being injected with infectious 
materials, receiving mutagens or carcinogens supplemented into their food 
or water will be housed in negative air-flow animal units. Cages will be 
labeled as to the type of hazard present, amount and route of exposure, and 
the date of administration. Signs placed on each unit will indicate if (1) 
animals are currently being exposed, (2) animals were exposed in the past, 
or (3) animals that were not exposed. 
• Biological Safety Cabinets–Biological safety cabinets provide sterile 
laminar airflow onto the work surface, containment of aerosols or droplets, 
and protection to the user. There are 3 different classifications of BSC: 
Class 1 to Class 3. The performance of BSC must be verified at the time of 
installation, whenever they are moved, and annually thereafter. For more 
information regarding BSC, see Appendix E and F of this plan and 
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Document 13.1, “Biological Controls and Operations,” of the ES&H 
Manual. 
• Containment Protection For Vacuum Systems–The aspiration of tissue 
culture media from monolayer cultures or of supernatants from centrifuge 
samples into primary collection flasks are a common laboratory procedure. 
Protection should be provided against drawing aerosols of hazardous 
chemical or biological materials or overflow fluid into the house vacuum 
system. This protection is provided by the use of an air filter (e.g., vacuum 
protection filter, 0.2 µm) in the line immediately leading into the house 
vacuum line and an overflow flask for liquids between the collection flask 
and the air filter. For more information regarding the assembly of this 
device, see Appendix A of this document. 
• Sharps Containers– "Sharp Containers" that have become 3/4 full should be 
disposed. See Section 5.1.5 for more information regarding waste disposal. 
• Engineered Sharps Injury Protection (ESIP)– If hypodermic syringe 
needles, surgical scalpels or other sharps must be used, they shall 
incorporate ESIP features whenever possible (e.g., re-sheathable, retractable 
scalpels, intrinsically-safe needles, blunt-tip needles). If a procedure using a 
needle does not require the piercing function, then a blunt-tipped needle 
should be used. All needles are to be disposed of in a properly labeled 
sharps container. 
5.3  Personal Protective Equipment 
Identifying and understanding the hazard and then matching the needed personal 
protective equipment to the workplace hazard is the key to selecting effective and 
appropriate protection. Respirators are not recommended and unnecessary when 
biological safety cabinets are available for use. 
Laboratory coats minimize skin exposure and protect street clothes from being 
contaminated. Laboratory coats must be worn while working in the laboratory and are not 
to be worn in non-laboratory areas (e.g., offices). The use of gloves and a face shield (in 
conjunction with eye protection) is highly recommended when splashing is anticipated 
and will be designated in appropriate safety documentation, such as the IWS, HAC, etc. 
Glove selection is important when dealing with a variety of chemicals and biological 
materials. Contact the ES&H Team Industrial Hygienist for more information regarding 
selection. Eye protection is required to be worn at all times while working in the 
laboratory. 
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6.0 Emergency Controls 
6.1 Handling Spills 
In any laboratory operation, the possibility of a spill exists. A thorough understanding of 
the potential hazards of the experiment, as well as careful planning of a spill response 
protocol, will help minimize personal injury and property damage. See Appendix D for 
more information regarding the clean up of small-scale spills. 
Lawrence Livermore National Laboratory Issued: 12/06 
Facility Safety Plan 360.1 Expires: 12/31/09 
Building 360 Complex, Biohazardous Operations Page 21 of 36 
 
 
 
7.0 Environmental Concerns and Controls 
Environmental concerns and controls are discussed in Section 5.8, “Environmental 
Hazards and Controls,” of FSP 360 and Document 36.1, “Hazardous, Radioactive, and 
Biological Waste Management Requirements,” of the ES&H Manual. Medical and 
biohazardous waste management is discussed in Section 5.1.3 of this addendum. 
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8.0 Emergency Response 
Emergency Response procedures are discussed in Section 8.0 of FSP 360. 
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9.0 Maintenance, Inspection, and Quality Assurance of Safety 
 Systems and Equipment 
All facilities included in this FSP are also included in Section 6.0 of FSP 360, which 
covers these issues. Specific to this FSP are BSCs, which are maintained by CMLS 
personnel. All BSCs receive yearly inspections and preventive maintenance by an 
approved vendor (Section 11, Ref. 11.7). 
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10.0  Training Requirements 
All training requirements are discussed in Section 7.0 of FSP 360. 
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Appendix A: Vacuum Line Filter 
 
The aspiration of tissue culture media from monolayer cultures or of supernatants from 
centrifuge samples into primary collection flasks is a common laboratory procedure. Protection 
should be provided against drawing aerosols of hazardous chemical or biological materials or 
overflow fluid into the vacuum system. This protection is provided by the use of an air filter in 
the line immediately leading into the house vacuum line and an overflow flask for liquids 
between the collection flask and the air filter. 
To assemble this protective apparatus, use flexible tubing of appropriate inside diameter for the 
flask and filter fittings and of sufficient wall thickness for the applied vacuum. Filter flasks of 
capacities from 250 to 4000 ml may be used for the overflow flask, depending on the available 
space and the amount of fluid that could be accidentally aspirated out of the collection flask. The 
overflow flasks should contain a disinfectant solution appropriate for the biohazardous material 
under study. It is essential that an antifoam agent, such as Dow Corning Antifoam A, be added to 
the overflow flask, since bubbling of air through the disinfectant will cause considerable foam 
that, if allowed to reach the filter, will shut off the vacuum. 
If the filter becomes contaminated or requires changing, the filter and flask can be safely 
removed by clamping the line between filter and vacuum source. The filter and flask should be 
autoclaved before the filter is discarded. A new filter can be installed and the assembly replaced. 
This protective apparatus for the vacuum system is shown in the figure below. A cartridge-type 
HEPA filter provides an effective barrier to passage of aerosols into the house vacuum system. 
The filter has a capacity to remove airborne particles 300 nm (0.30 mm) or larger in size. 
 
 
Reference: NIH Laboratory Safety Monograph, A supplement to the NIH Guidelines for 
Recombinant DNA Research, July 1978. 
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Appendix B: Universal Precautions 
 
Universal precautions shall be followed to prevent contact with blood and other potentially 
infectious materials to reduce the risk of occupational exposure. Universal precaution is an 
approach to infection control where all human blood and certain human body fluids are treated as 
if known to be infectious for HIV, HBV, and other blood borne pathogens. The following 
precautions are advocated by CDC for health care workers: 
1. All healthcare and laboratory workers will use appropriate barrier precautions to prevent skin 
and mucous membrane exposure when contact with blood or bodily fluids are anticipated. 
2. Gloves must be worn when touching blood, bodily fluids, mucous membranes, or non-intact 
skin. 
3. Gloves must be worn when handling items or surfaces contaminated with blood and bodily 
fluids. 
4. Gloves must be worn while performing venipuncture and other vascular access procedures. 
5. Gloves must be changed after contact with each patient. 
6. Mask and protective eyewear or face shields should be worn during procedures that are likely 
to generate droplet of blood or other bodily fluids in order to prevent exposures of the mucus 
membranes of the mouth, nose, and eyes. 
7. Gowns or aprons should be worn during procedures that are likely to generate splashes of 
blood or other bodily fluids. 
8. Hands and other skin surfaces should be washed immediately and thoroughly with water and 
antiseptic cleanser if contaminated with blood or other bodily fluids. 
9. Hands should be immediately washed after gloves are removed. 
10. Employee must take precautions to prevent injuries caused by needles, scalpels, and other 
sharp instruments or devices during or after medical procedures, when cleaning instruments, 
and during disposal of used needles. 
11. To prevent needle-stick injuries, needles should not be recapped, bent or broken by hand, 
removed from disposable syringes, or otherwise manipulated by hand. 
12. After they are used, disposable syringes, needles, scalpels blades, and other sharp items must 
be placed in puncture-resistant containers for disposal. These containers should be as close as 
practical to the area where disposable sharps are used. 
13. Laboratory personnel who have exudative lesions or weeping dermatitis must refrain from 
handling clinical samples or specimens and contaminated equipment until the condition is 
resolved. 
14. Pregnant employees should review safe work procedures with supervisors & HCD. 
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15. Management of regulated waste shall be managed according to guidance in Section 5.1.7 of 
this addendum and Section 5.8 of the Building 360 Complex FSP. 
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Appendix C: Disinfectants 
Chemical Disinfectants 
Pertinent characteristics and potential application for several categories of chemical disinfectants 
most likely to be used are summarized below. 
Alcohol 
A concentration of 70 - 80% by weight of Ethyl or isopropyl alcohol is commonly used as a 
general disinfectant. Alcohol will denature proteins and is somewhat slow in their germicidal 
action. Although they are good general disinfectants, they exhibit no activity against bacterial 
spores. Concentrations greater than 80% are less effective. 
Chlorine 
This halogen is a universal disinfectant that is active against all microorganisms, and bacterial 
spores. Free, available chlorine is an active element. Chlorine combines with protein (e.g. 
organic matter) and rapidly decreases in concentration in its presence. It is a strong oxidizing 
agent that is corrosive to metals. If used directly on a stainless surface, rinse thoroughly with 
water after decontamination to prevent tarnishing. 
Chlorine solutions have a limited shelf life and will gradually lose its strength over time. Fresh 
solutions must be prepared frequently. Sodium hypochlorite is usually used as a base for chlorine 
disinfectant. For disinfecting purposes, a concentration of between 5,000 and 10,000 ppm of 
available chlorine is sufficient. Household or laundry bleach usually contains 5.25% available 
chlorine or 52,500 ppm. A 1 to 10 diluted solution will contain 5,250 ppm of available chlorine. 
Decontamination with this concentration will require a 30-minute contact time. Do not 
autoclave chlorine solutions or materials treated with them. The residual chlorine will 
vaporize and result in an inhalation hazard. 
Iodophor 
The most widely used groups of disinfectants in laboratories are iodophors (e.g., Wescodyne). 
Manufacturers recommend dilution ranges from 1 oz in 5 gal of water (25 ppm) to 3 oz in 5 gal 
(75 ppm or 0.0075%) of water. The disinfectant characteristics of iodophor are similar to 
chlorine in that small amount of iodophors can be rapidly taken up by extraneous protein. Clean 
surfaces or clear water can be effectively treated by 75 ppm available iodine, but difficulties may 
be experienced if any appreciable amount of protein is present or when the pH is below 6 or 
above 7. For washing hands or for use as a sporicide, it is recommended that Wescodyne be 
diluted 1 to 10 in 50% ethyl alcohol. This will yield 1,600 ppm of available iodine; a relatively 
rapid inactivation of all microorganisms will occur. 
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Appendix C: Disinfectants (continued) 
Quaternary Ammonium Compounds or Quats 
After years of testing and use, there is still considerable controversy about the efficiency of the 
“Quats” as disinfectants. These cationic detergents are strongly surface-active, and this detergent 
property makes them good surface cleaners. They will attach to protein and will lose 
effectiveness in the presence of proteins. The Quats tend to clump microorganisms and are 
neutralized by anionic detergents such as soap. Quats are bacteriostatic, tuberculostatic, 
sporostatic, fungistatic, and algistatic at low concentrations. They are biocidal against lipophilic 
viruses at medium concentrations, but they are only biostatic virucidal against hydrophilic 
viruses even at high concentrations. The Quats have the advantages of being odorless, 
nonstaining, noncorrosive to metals, stable, inexpensive and relatively non-toxic. Caution should 
be used when handling concentrated Quats; even a small droplet splashed into the eyes may 
cause damage to tissues. Be sure to wear safety glasses and proper personal protective 
equipment when handling these disinfectants. The concentration of the disinfectant used should 
be made in accordance to manufacturer’s specification on the label. 
Formaldehyde 
Formaldehyde for use as a disinfectant is usually marketed as formalin solution (37% 
concentration of the gas in water), or as paraformaldehyde, a solid polymerized compound. 
Formaldehyde containing a >5% active ingredient is an effective liquid disinfectant but loses its 
disinfectant activity at 4˚C or less. It is pungent and irritating odor and is a human carcinogen. 
Formaldehyde vapor generated from formaldehyde solution is an effective space disinfectant for 
sterilizing rooms or buildings. Formaldehyde gas can be generated by heating paraformaldehyde 
crystals. Formaldehyde vapors and gas are toxic and can elicit hypersensitivity and/or irritation. 
Dilution should be made in a chemical fume hood. Respiratory protection may be necessary. 
Formaldehyde gas is flammable and may be explosive under certain conditions. 
Phenol 
Phenol itself is not often used as a disinfectant. The odor is somewhat unpleasant, and a gummy 
residue remains on treated surfaces. This is especially true during steam sterilization. Although 
phenols itself may not be in widespread use, phenol homologs and phenolic compounds are 
bases of a number of popular disinfectants. The phenolic compounds are effective disinfectants 
against some viruses, rickettsiae, fungi and vegetative bacteria. The phenolics are not effective in 
ordinary use against bacterial spores. 
Concentrated phenolics should be used carefully; even a small droplet splashed into the 
eyes may cause damage to tissues. Phenolics are readily absorbed by the skin and splashes can 
lead to local irritations, severe bums, and systemic poisoning leading possibly to death. 
Consequently, safety glasses and other proper personal protective equipment should be worn. 
Contaminated skin should be washed aggressively with water. 
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Appendix C: Disinfectants (continued) 
Other Vapors and Gases 
Vaporous Hydrogen Peroxide (VHP) is found to be an effective disinfectant. When used in 
closed systems and under controlled conditions of temperature and humidity, excellent 
decontamination results can be obtained.  
Cautions Required When Applying Chemical Disinfectants 
When handling concentrated stock solutions of certain disinfectants, be aware of the potential 
hazards and exercise caution. Concentrated quaternary and phenolic disinfectants are particularly 
harmful to the eyes. Even a small droplet splashed in the eyes may cause blindness. Absorption 
of phenolic compounds by the skin can lead to local irritation, severe burns, and to systemic 
poisoning leading possibly to death. Constant or prolonged exposure to phenol may cause 
headache, dizziness, difficulty in swallowing, diarrhea, vomiting, shock, convulsions, and death. 
Safety glasses and proper personal protective clothing should be worn to avoid corrosion and 
depigmentation of the skin. Good ventilation is required when working with phenol to minimize 
inhalation. 
Vapors of formaldehyde can elicit hypersensitivity and irritation; they are also toxic and working 
in a chemical fume hood is highly recommended. Respiratory protection may be necessary. 
Pertinent characteristics and potential applications for several categories of chemical 
disinfectants most likely to be used in the biological laboratory are summarized in the ES&H 
Manual, Document 13.1, “Biological Controls and Operations,” Section 3.0, Table-2 “Summary 
of liquid, gaseous, and physical decontamination agents for biological agents and toxins” 
(http://www.llnl.gov/es_and_h/hsm/chapter_3.0/chap3.0.html#3.0.2). The suggested practical 
concentrations and contact times may differ markedly from the manufacturer's recommendations. 
The efficacy of any of the disinfectants should be conclusively determined by individual 
investigators. 
*Wastes associated with the application of disinfectants will be managed according to the 
guidance in Section 5.1.7 of this addendum and Section 5.8 FSP 360. 
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Appendix D: Emergency Response 
Handling Spills 
In any laboratory operation, the possibility of a spill exists. A thorough understanding of the 
potential hazards of the experiment, as well as careful planning of a spill response protocol, will 
help minimize personal injury and property damage. While the severity of the accident will 
dictate the response required, the general recommended approach listed below should be 
followed. 
First Priority: Protect Personnel 
• Notify your supervisor and Hazards Control Department personnel from the nearest 
phone. Do not contaminate the phone. If the spill is large or Hazards Control Department 
personnel fail to respond quickly enough, call 911 and report the spill. 
• Notify all personnel in the immediate area. Evacuate the immediate room or area if the 
accident is hazardous to anyone or if there is doubt about the extent of the hazard. 
• When the agent involved may be hazardous when inhaled, hold your breath as much as 
possible while evacuating the area. Administer first aid when necessary. Remove 
contaminated clothing and shoes and leave the area. Wash hands, face and other 
contaminated portions of the body with appropriate disinfectant and soap. If eyes or other 
part of the body has been contaminated, flush the affected areas with water for fifteen 
minutes. 
• Secure the area of the spill and prevent people from entering the area. Post the entrance 
specifying (1) the type of accident, the agent(s) involved, (2) date and time of the 
accident, and (3) the name of person(s) to contact prior to entering the area. Report to 
LLNL Health Services for evaluation. 
Second Priority: Protect Equipment and Facility through Proper Cleanup and 
Decontamination. 
• Proceed only after consultation with, and approval from, Hazards Control. 
• Reenter the area after allowing at least 30 minutes for aerosols to settle. 
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Appendix D: Emergency Response (Continued) 
• If the spill took place in the open laboratory, decontamination may range from flooding 
the area with an appropriate disinfectant to fumigating the entire room with disinfectant 
chemical vapor, depending on the nature and scale of the spill. The disinfectants used 
should be applied from the outside into the spill to prevent further contamination. Use of 
appropriate personal protective equipment varies according to the level of hazard 
involved. In general, it may involve some or all of the following: coveralls, gloves, shoe 
covers, head cover, and respiratory protection. 
• If the spill took place within a biological safety cabinet, initiate chemical disinfection 
procedures while operating the cabinet ventilation system to prevent the escape of the 
contaminants from the cabinet. Appropriate gloves should be worn. Use sufficient 
disinfectant to assure the disinfection of the drain pans and catch basins below the work 
surface. Lift the front exhaust grill and tray and wipe all surfaces. Wipe the catch basin 
and drain the disinfectant into a container. This procedure will not disinfect the filters, 
blower, air ducts or other interior parts of the cabinet. Contact Hazards Control for 
decontamination of the entire cabinet. 
• If the spill involved a radioactive biohazardous material, the cleanup procedure may have 
to be modified depending on the relative risk assessment of the biological and the 
radiological hazards involved. Contact Hazards Control for specific details. 
• If the spill involved a hazardous biohazardous material, special equipment and/or 
reagents may be required. Contact Hazards Control for specific details. 
• Regulated wastes generated from emergency response activities will be managed 
according to guidance described in the Building 360 Complex FSP. 
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 Appendix E: Biological Safety Cabinets 
Procedures for Effective Use 
 
General Operating Information 
Understand how the cabinet works, and plan work accordingly. Protect yourself, your research, 
and your co-workers. 
Keep the laboratory meticulously clean. Minimize storage of boxes and supplies, particularly 
near the biological safety cabinet (BSC). Wash hands thoroughly before and after working in the 
BSC. Wearing a clean laboratory coat and gloves while working in a BSC increases safety and 
helps reduce contamination of research materials. 
The effectiveness of the BSC is a function of directional airflow (inward and downward, through 
high efficiency filters). Anything that disrupts the air flow patterns can reduce cabinet 
effectiveness. Some examples are: (1) rapid movement of arms in and out of the BSC, (2) people 
walking rapidly past the opening of the BSC, down-drafts from ventilation systems; and (3) 
opened laboratory doors. 
Operational Procedures 
• Turn off the BSC ultraviolet (UV) lamp if in operation and turn on the BSC. Wipe work 
surface and the front window glass with the appropriate germicide (70% ethanol, 1:10 
bleach solution). Wipe off each item needed for the procedure and place in the cabinet. 
Allow the cabinet to run for at least 5 minutes before beginning work. Use of UV lamps 
for “disinfection” is discouraged. If used, turn off prior to other work. 
• Do not place any objects over the front grille and do not block the rear exhaust grille. 
Work should be performed at least 6 inches back from the front grille. 
• Segregate contaminated items away from clean items. Minimize movement of 
contaminated items over clean ones. Remember to work from the clean side to the dirty 
side. 
• Put on a laboratory coat and thoroughly wash hands. Put on gloves, as appropriate. 
• Follow good microbiological techniques, such as holding open tubes and bottles as 
horizontal as possible. Use convenient mechanical pipetting aids. Do Not Mouth Pipette. 
Place horizontal pipette discard pans containing appropriate disinfectant or water inside 
the BSC. Do not use vertical pipette discard canisters on the floor outside the BSC. 
• The heat from the open flame creates turbulence in airflow and will compromise sterility; 
heat buildup may damage the filters. If flaming is required, use a bunsen burner with a 
pilot light or an electric loop incinerator. 
• If items need to be removed from the BSC or new items introduced, arms shall be slowly 
moved in and out of the cabinet to minimize airflow disruption. 
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Appendix E: Biological Safety Cabinets  
Procedures for Effective Use (continued) 
 
• If there is a need to use a piece of equipment that creates turbulence in the BSC (e.g., 
centrifuge, blender, sonicator), place equipment in the back 1/3 of the cabinet and stop 
work while equipment is operating. 
 
• Protect the building vacuum system from contamination by placing a cartridge filter 
between the vacuum trap and the source. See Appendix A for more information. 
 
• Clean-up any spills in the BSC immediately. See Appendix B for more information and 
guidance. 
 
• Remove all materials and wipe all interior surfaces with 70% alcohol when finished 
work. Let the cabinet run 10 minutes, then turn it off. Examine the tray under the work 
surface, disinfect and clean as necessary. 
 
• Segregate waste by category and then properly dispose. Refer to Section 6.0 of FSP 360 
for detailed environmental controls. 
 
• Remove laboratory coat and wash hands thoroughly before leaving the laboratory. 
 
 
Reference: NIH Laboratory Safety Monograph, A supplement to the NIH Guidelines for 
Recombinant DNA Research, July 1978. 
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Appendix F: Biological Safety Cabinets 
Necropsy Rules for Infected Animals 
 
1. Necropsy of infected animals should be carried out in biological safety cabinets by 
trained personnel. 
 
2. Surgeons' wrap around gowns should be worn over laboratory clothing during necropsy. 
 
3. Rubber gloves should be worn when performing necropsies. 
 
4. The inside of biological safety cabinets and other potentially contaminated surfaces 
should be disinfected with a suitable germicide at the initiation and termination of the 
necropsy. 
 
5. The fur of the animal should be wetted with a suitable disinfectant. 
 
6. Small animals should be pinned down or fastened on wood or metal in a tray. 
 
7. Upon completion of necropsy, all potential biohazardous materials should be placed in 
suitable containers and sterilized. Contaminated mixed waste is segregated and stored for 
appropriate disposal. 
 
8. Contaminated instruments should be placed in a horizontal bath, located within the 
biological cabinet containing suitable disinfectant. 
 
9. Grossly contaminated rubber gloves should be cleaned in disinfectant before removal 
from the hands, remove to check for holes, and then sterilize for reuse or decontaminate 
prior to disposal. Wearing gloves is not a substitute for hand-washing; hands should be 
washed after necropsy and carcass disposal. 
 
10. Dead animals are to be placed into a plastic bag, tied into a knot or taped closed at end. 
The bag is placed into a second plastic bag and closed. A cardboard tag, with string, is 
filled out with date, name of investigator, species of animal, number of animals, name of 
agent animals are infected with, amount of agent animals received and tied around neck 
of plastic bag. The tagged bag is placed into the appropriate ACF freezer, plastic lined, 
properly labeled cardboard box. All information is entered into freezer logbook. Filled 
boxes will be properly packaged for removal by RHWM and shipped to contract agency 
for incineration. 
 
 
Reference: NIH Laboratory Safety Monograph, A supplement to the NIH Guidelines for 
Recombinant DNA Research, July 1978. 
 
 
